ESSEX BIO-TECH (01061) announces its interim performance: a net profit of HKD 163 million for the period, representing a year-on-year increase of 3.79%.

26/08/2025

Yisheng Biological Technology (01061) announced its interim performance for the six months ending June 30, 2025, with a revenue of 8...

Essex Bio-Tech (01061) announced its interim performance for the six months ending June 30, 2025, with revenue of HK$877 million, a year-on-year increase of 5.79%; net profit for the period was HK$163 million, a year-on-year increase of 3.79%; basic earnings per share were 28.82 HK cents; it plans to pay a interim dividend of HK 7 cents per share.

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.

AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.

I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.

Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.